For all the buzz around the Inflation Reduction Act (IRA), opinions on its impact are sharply divided – especially in the life sciences sector. Critics argue that the IRA’s drug pricing provisions, particularly Medicare price negotiation, will stifle innovation by reducing incentives for pharmaceutical companies to invest in research and development.  But these concerns don’t…